Loading…
Loading…
QBIO (Q BioMed Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
GeneDx (NASDAQ: WGS - Get Free Report) and Q Biomed (OTCMKTS:QBIO - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings. Risk and Volatility GeneDx has a beta of 2.17,
Establishment Labs (NASDAQ: ESTA - Get Free Report) and Q Biomed (OTCMKTS:QBIO - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, dividends, earnings and risk. Valuation and Earnings This table compares Establishment Labs
Auna (NYSE: AUNA - Get Free Report) and Q Biomed (OTCMKTS:QBIO - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends. Volatility and Risk Auna has a beta of 2.26,
Q Biomed (OTCMKTS:QBIO - Get Free Report) and GoodRx (NASDAQ: GDRX - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership. Institutional and Insider Ownership 63.8% of GoodRx shares are
Q Biomed (OTCMKTS:QBIO - Get Free Report) and SBC Medical Group (NASDAQ: SBC - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk. Earnings and Valuation This table compares Q
Q BioMed Inc. (OTCQB:QBIO) said it has received a patent in the US and a notice of allowance in Europe for the Uttroside B chemotherapeutic asset, adding to the already issued patents in Korea, Canada and Japan, which the company says shows tremendous value in the liver cancer market for the asset and which also has Orphan Drug designation from the US Food and Drug Administration (FDA). The biotech acceleration and commercial stage company said it has exclusive rights to the technology through an agreement with the Rajiv Gandhi Centre for Biotechnology, an Autonomous Institute under the Department of Biotechnology, Government of India, and the Oklahoma Medical Research Foundation.
Q BioMed Inc. (OTCQB:QBIO) has received a notice of an allowable patent from the US Patent Office related to its liver cancer treatment Uttroside B. The company already holds patents in Korea, Canada and Japan, and Uttroside B previously received Orphan Drug designation from the US Food and Drug Administration.
Q BioMed Inc has given itself a big shot in the arm, adding a multi-million dollar asset in the form of an equity stake in long term partner Mannin Research, which has a drug development pipeline poised to be a multi-billion dollar blockbuster franchise for years to come. The company has converted its long-term royalty agreement into a 15% equity stake in private Mannin - a holding, which has a current valuation of C$30 million.